

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254,
Wellington 6001, New Zealand
Phone 64 - 4 - 460 4990
Fax 64 - 4 - 460 4995
www.pharmac.govt.nz

30 January 2006

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

By facsimile (1page)

PROPOSED LISTING OF ASPIRIN 100 MG (CARTIA) IN THE PHARMACEUTICAL SCHEDULE.

PHARMAC has entered into a provisional agreement with GlaxoSmithKline NZ Limited in relation to the listing of Cartia in the Pharmaceutical Schedule. The details of the proposed changes are as follows:

- Cartia would be listed in Section B of the Pharmaceutical Schedule from 1 April 2006 at the following price and subsidy:

Chemical	Presentation	Strength	Brand	Price and Subsidy	Pack Size
Aspirin	Tablet	100 mg	Cartia	\$5.70	168 tablets

Prices and subsidies are ex-manufacturer, ex-GST.

- Cartia 100 mg would be protected from tendering and reference pricing until 1 July 2007.
- The Multichem brand of 100 mg aspirin would be reference priced to Cartia from 1 September 2006 at the following price and subsidy:

Pharmaceutical	Presentation	Strength	Brand	Pack Size	Current Price and Subsidy	Proposed New Subsidy
Aspirin	Tablet	100 mg	Multichem	30	\$1.20	\$1.02

Prices and subsidies are ex-manufacturer, ex-GST.

If you wish to make comments regarding this proposal for the PHARMAC Board to consider when making its decision, please forward them to PHARMAC by **5:00pm, Friday, 17 February 2006**.

Yours sincerely



Stephen Woodruffe
Therapeutic Group Manager Intern